#JPM22 - The gene editing revolution: Now it's time for human data to define a fast-changing field
Okay everybody, I’m John Carroll. I’m the editor of Endpoints News. I appreciate the audience for joining us. I’m here with a great group of people to talk about probably the most interesting thing that’s going on in R&D right now within the whole biopharma industry. I think certainly there’s been a tremendous amount of interest in it. There’s been a lot of interest in this particular panel, I think because of the people that we’ve got here for this one. I’m joined by David Liu from The Broad, Sekar Kathiresan, CEO of Verve, Patrick Hsu from Berkeley and Nicole Gaudelli, the gene editing platform technology chief for Beam.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters